Biogen (BIIB) Equity Average (2009 - 2026)

Biogen (BIIB) has reported Equity Average for 18 consecutive years, with $18.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Average rose 9.54% year-over-year to $18.5 billion; the TTM figure through Mar 2026 stood at $18.5 billion (up 9.54% YoY), while the FY2025 annual figure was $17.5 billion, up 10.97% from the prior year.
• Equity Average came in at $18.5 billion for Q1 2026 at Biogen, up from $9.2 billion in the prior quarter.
• The five-year high for Equity Average was $18.5 billion in Q1 2026, with the low at $8.8 billion in Q3 2025.
• Average Equity Average over 5 years is $14.0 billion, with a median of $14.5 billion recorded in 2023.
• Across the five-year window, Equity Average climbed 22.52% in 2023 and plunged 45.16% in 2025, its largest moves.
• Year by year, Equity Average stood at $13.1 billion in 2022, then gained by 11.94% to $14.6 billion in 2023, then grew by 12.96% to $16.5 billion in 2024, then slumped by 44.65% to $9.2 billion in 2025, then soared by 101.59% to $18.5 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $18.5 billion, $9.2 billion, and $8.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.